TB

This application, created by the WMA and the New Jersey Medical School Global Tuberculosis Institute, gives physicians the flexibility to access the course material at any time, even when they are discussing treatment options with their patients. The application was developed in collaboration with the World Health Organization with financial support from the Eli Lilly MDR-TB partnership. The application contains the eight training modules which comprise the WMA's course on MDR-TB.

This document revises previous WHO standard case definitions for TB and drug-resistant TB, the categories used to assign outcomes, and the standard reporting framework for TB.

This tool is designed to support the effective monitoring and evaluation (M&E) of tuberculosis (TB) control programs in refugee camps and other settings located in resource-poor areas.

This guide was developed to help advocacy, communication, and social mobilization (ACSM) programs at national and subnational levels strengthen routine monitoring and evaluation of tuberculosis ACSM activities.

The Latent TB Infection (LTBI) Treatment Fact Sheet Series is designed to complement patient education delivered by healthcare professionals. For each of the three CDC-recommended LTBI regimens, there is a fact sheet in the series that can be personalized for individual patients. Each sheet provides patients with a written reminder of their treatment regimen, medication side effects, actions to take if side effects do occur, tips to help remain adherent to the medication, and instructions in the event a dose of medication is missed.

This fact sheet describes the impact of HIV-TB co-infection. It also presents work currently being done to find and treat HIV-TB.

Based on The Union's 93-years of working in the field, the new guide tackles the challenges of fulfilling each patient's potential for cure from both the clinician's and the programme manager's perspective.

The Tuberculosis Drug Information Guide, 2nd edition, is derived from Drug-Resistant Tuberculosis: A Survival Guide for Clinicians (2nd edition) produced in 2008. Two additional drugs, ofloxacin and clarithromycin (which are used primarily outside of the US), have been included. This Guide can help any physician, nurse, or pharmacist who participates in the management of patients with TB or LTBI.

This interim guidance provides advice on the inclusion of bedaquiline in the combination therapy of MDR-TB in accordance with the existing WHO Guidelines for the Programmatic Management of Drug-resistant TB (2011 Update).

This video provides information on MDR-TB.